Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Biotechnology

Healthcare
$6.77 +1.96%

+$0.19 today

Market cap
$68.98M
Beta
0.11
P/E (TTM)
-14.7
EPS (TTM)
-$0.67
52W Low $3.92High $19.15

Volume 0.02M

Average 1.40M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$50.94M

FY 2025 · Annual

Investing Cash Flow

$18.15M

FY 2025 · Annual

+110.4% YoY

Financing Cash Flow

$16.10M

FY 2025 · Annual

-72.8% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(340.14M)(228.3M)(276.13M)(85.4M)32.69M
Depreciation & Amortization9.35M5.65M4.83M5.05M2.38M
Deferred Income Tax1.79M0000
Stock-Based Compensation53.87M53.84M45.39M27M9.75M
Change in Working Capital52.58M(61.47M)15.34M(30.96M)(104.74M)
Accounts Receivables264K(39.24M)6.11M32.63M229K
Inventory3.34M(1.59M)(8.12M)(4.43M)10.66M
Accounts Payables9.07M(9.21M)(3.13M)687K(4.24M)
Other Working Capital39.91M(11.44M)20.48M(59.84M)(111.38M)
Other Non-Cash Items2.04M(40.15M)17.59M15.59M8.98M
Operating Cash Flow(220.52M)(270.43M)(192.98M)(68.72M)(50.94M)
Capital Expenditures(10.58M)(4.19M)(1.22M)(246K)0
Acquisitions (Net)(32.84M)000948K
Purchases of Investments(301.13M)(180.59M)(83.65M)(19.67M)(7.89M)
Sales of Investments333.97M292.97M208.71M28.54M25.09M
Other Investing Activities32.84M94.77M25K00
Investing Cash Flow22.26M202.96M123.87M8.62M18.15M
Debt Repayment(254K)(518K)(947K)(892K)(250K)
Common Stock Issued98.7M21.89M2.14M59.95M16.35M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities5.5M31.71M821K223K(1K)
Financing Cash Flow103.94M53.08M2.01M59.28M16.1M
Effect of Forex Changes00000
Net Change in Cash(94.32M)(14.39M)(67.1M)(811K)(16.69M)
Free Cash Flow(231.1M)(274.62M)(194.2M)(68.96M)(50.94M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income$32.7M
+ D&A$2.4M
+ Stock-Based Comp$9.8M
+ Deferred Tax$0
- Working Capital-$104.7M
+ Other Non-Cash$9.0M
= Operating Cash Flow-$50.9M
- Capex$0
= Free Cash Flow-$50.9M

Analysis

FY2025 free cash flow is -$50.9M. FCF conversion is -155.8% of net income. Operating cash flow was -$50.9M, with capex of $0. The largest bridge item is Working Capital at -$104.7M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
S-3S-3 filingNov 10, 2026
8-KCurrent reportNov 10, 2026
10-QQuarterly reportNov 10, 2026
4Statement of changes in beneficial ownershipSep 4, 2026
4Statement of changes in beneficial ownershipAug 26, 2026

Does ATRA generate free cash flow?

Atara Biotherapeutics, Inc. (ATRA) generated -$50.94M of free cash flow in fiscal 2025.

How much operating cash flow does ATRA produce?

Operating cash flow was -$50.94M, before capital expenditures of $0.00.